IOVA - Iovance Biotherapeutics, Inc.

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Show:
Balance sheet
Cash flow
Annual

Income statement

All numbers in thousands
Breakdown
ttm
31/12/2022
31/12/2021
31/12/2020
31/12/2019
Total revenue
0
0
0
0
0
Operating expenses
Research development
289,824
294,781
259,039
201,727
166,023
Selling general and administrative
101,483
104,097
83,664
60,210
40,849
Total operating expenses
391,307
398,878
342,703
261,937
206,872
Operating income or loss
-391,307
-398,878
-342,703
-261,937
-206,872
Income before tax
-389,904
-395,893
-342,252
-259,581
-197,556
Income from continuing operations
-389,904
-395,893
-342,252
-259,581
-197,556
Net income
-389,904
-395,893
-342,252
-259,581
-197,556
Net income available to common shareholders
-389,904
-395,893
-342,252
-259,581
-197,556
Basic EPS
-
-2.49
-2.23
-1.88
-1.59
Diluted EPS
-
-2.49
-2.23
-1.88
-1.59
Basic average shares
-
159,259
153,406
138,301
124,336
Diluted average shares
-
159,259
153,406
138,301
124,336
EBITDA
-
-398,878
-342,703
-260,797
-206,872